eBioscience™ Human IL-28, Recombinant Protein, Carrier-Free

Human Recombinant Protein

Brand: Affymetrix eBioscience

Manufacturer Part Number: 34-8363-64

Code: NEW

Additional Details:
Additional Details: Weight: 0.09500kg

Product Code. 15558796

Quantity Price
1 £ 133.91 / 20µg
EU Stock 1
Add to basket

Description and Specification


Cross Reactivity Human
Name IL-28
Source E. coli
Formulation Lyophilized from 10mM acetic acid
Storage Requirements Store lyophilized protein at less than or equal to -20°C. Reconstituted protein solution can be stored with carrier protein (e.g., 0.1% BSA) at less than or equal to -20°C.
Molecular Weight 19.6kDa
Purification Method SDS-PAGE and HPLC
Endotoxin Concentration Less than 0.1ng/μg cytokine as determined by the LAL assay
Recombinant Yes
Regulatory Status RUO
Quantity 20μg
Gene Symbol Interleukin-28A, Interferon lambda 2
Biological Activity The ED50 of this protein, as measured by activation of STAT phosphorylation in human colon carcinoma cells, is 0.3-0.5ng/mL.
Purity >98%
Structural Form E. coli (amino acids Pro27-Val200; Accession # NP_742150)
For Use With (Application) Functional Assays
Product Type Recombinant Protein, Carrier-Free
Conjugate Unlabeled

IL-28A belongs to the IFN lambda family, a novel family of cytokines within the IL-10 superfamily. The three members of this family are IL-29 (IFN lambda 1), IL-28A (IFN lambda 2), and IL-28B (IFN lambda 3), and are also known as the type III Interferons.

The IFN lambdas signal through a heterodimeric receptor of which one subunit, IL-10R2, is shared with other members of the superfamily. The second subunit, IFN lambda R1 or IL-28R alpha, is unique to the IFN lambdas. Signaling occurs through the Jak/STAT pathway in a similar manner as the type I IFN (IFN alpha/beta) and activates many of the same genes despite low sequence homology between the cytokines and receptors in the two families. Both IFN families display antiviral activity through the induction of antiviral protein production in target cells and the upregulation of MHC class I expression. These proteins also exhibit antiproliferative and antitumor effects, making them a possible alternative to IFN alpha cancer therapies. Unlike the type I IFN, which are able to stimulate most cells, response to IFN lambda stimulation appears to be limited to dendritic and some tumor cells due to the limited expression of IFN lambda R1. Another notable difference is the ability of the IFN lambda stimulation to drive dendritic cells towards the production of CD4+CD25+FoxP3+ regulatory T cells, suggesting a possible immunoregulatory role